Next Article in Journal
Influence of Plant Growth Retardants on Quality of Codonopsis Radix
Previous Article in Journal
Gypmacrophin A, a Rare Pentacyclic Sesterterpenoid, Together with Three Depsides, Functioned as New Chemical Evidence for Gypsoplaca macrophylla (Zahlbr.) Timdal Identification
Article Menu
Issue 10 (October) cover image

Export Article

Open AccessArticle
Molecules 2017, 22(10), 1615; doi:10.3390/molecules22101615

Solid-State Form Characterization of Riparin I

1
Pharmaceutical Sciences Departament, Federal University of Paraíba, University City, João Pessoa PB 58059-970, Brazil
2
Biotechnology Departament, Federal University of Paraíba, University City, João Pessoa PB 58059-970, Brazil
3
Pharmaceutical Sciences Departament, Federal University of Piauí, Teresina PI 64600-000, Brazil
*
Author to whom correspondence should be addressed.
Received: 27 August 2017 / Accepted: 22 September 2017 / Published: 9 October 2017
View Full-Text   |   Download PDF [5747 KB, uploaded 9 October 2017]   |  

Abstract

Riparin I is an alkamide with potential anxiolytic activity in preclinical studies. The characterization and understanding of solid-state properties play an importance role in drug development. For this work, the solid state of five riparin I batches (RIP-1, RIP-2, RIP-3, RIP-4, and RIP-5), obtained by the same synthesis process, were characterized by Scanning Electron Microscopy (SEM), Differential Scanning Calorimetry (DSC), DSC-photovisual, Thermogravimetry (TG), Fourier Transform Infrared (FTIR), Pyrolysis (Pyr-GC/MS), X-ray Powder Diffraction (PXRD), and Solid-State Nuclear Magnetic Resonance (ssNMR) techniques. Batches of riparin I with different crystal habits resulting in crystallization impurities were observed, which can be attributed to the presence of triethylamine. The main differences were observed by DSC, PXRD, and ssNMR analysis. DSC curves of RIP-2 and RIP-3 presented endothermic peaks at different temperatures of fusion, which can be attributed to the mixture of different crystalline forms. PXRD and ssNMR results confirmed crystallinity differences. The results offer evidence of the importance of controlling the reproducibility of the synthesis in order to obtain the adequate morphology for therapeutic efficacy and avoiding future problems in quality control of riparin I products. View Full-Text
Keywords: riparin I; solid-state characterization; pharmaceutical analysis riparin I; solid-state characterization; pharmaceutical analysis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

de Moura, E.A.; Terto, M.V.C.; de Moura Mendonça, E.A.; Procópio, J.V.V.; de O. Costa, V.C.; Barbosa Filho, J.M.; Chavez Gutierrez, S.J.; Tavares, J.F.; Oliveira Macedo, R.; da Silva, M.S. Solid-State Form Characterization of Riparin I. Molecules 2017, 22, 1615.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top